Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall St choppy as megacap losses offset chip gains before Fed decision
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise about 2% as Yemen fighting stokes supply fears
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
| (NASDAQ: PTGX) | Delayed: 142.69 +1.57 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $141.12 | 52 Week High | $24.52 | |||
| Open | $139.35 | 52 Week Low | $10.02 | |||
| Day High | $143.26 | P/E | N/A | |||
| Day Low | $138.29 | EPS | $0.00 | |||
| Volume | 89,894 | |||||
